Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DES (drug-eluting stents) market prompts Johnson and Johnson into Cordis move

This article was originally published in Clinica

Executive Summary

As part of Johnson and Johnson's plan to improve overall cost structure, its cardiovascular group company Cordis will undergo job cuts and a re-modelling of its business strategy. The Miami Lakes, Florida company is looking to address the changing market aspects for drug-eluting stents (DESs) and also enhance it patient treatment, whilst reducing its cost base. Sales of its Cypher drug-coated stents fell by 41% in the second quarter of 2007, according to J&J. Company chairman and CEO William Weldon assured patients and employees that the group still sees Cordis as an integral part of its business. "We remain committed to the drug-eluting stent market, and we have new products in development across our cardiovascular franchises," said Mr Weldon.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049343

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel